EA202191060A1 - ANTI-NPR1 ANTIBODIES AND THEIR APPLICATION - Google Patents

ANTI-NPR1 ANTIBODIES AND THEIR APPLICATION

Info

Publication number
EA202191060A1
EA202191060A1 EA202191060A EA202191060A EA202191060A1 EA 202191060 A1 EA202191060 A1 EA 202191060A1 EA 202191060 A EA202191060 A EA 202191060A EA 202191060 A EA202191060 A EA 202191060A EA 202191060 A1 EA202191060 A1 EA 202191060A1
Authority
EA
Eurasian Patent Office
Prior art keywords
npr1
antibodies
application
bind
npr1 antibodies
Prior art date
Application number
EA202191060A
Other languages
Russian (ru)
Inventor
Майкл Данн
Цзя Су
Джейсон Местейтис
Джеспер Громада
Лори МОРТОН
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2019/057033 external-priority patent/WO2020086406A2/en
Publication of EA202191060A1 publication Critical patent/EA202191060A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к моноклональным антителам, которые связываются с белком-рецептором натрийуретического пептида 1 (NPR1), и способам их применения. В различных вариантах осуществления изобретения антитела представляют собой полностью человеческие антитела, которые связываются с NPR1. В некоторых вариантах осуществления антитела по изобретению полезны для активации активности NPR1, таким образом обеспечивая средства лечения или профилактики NPR1-ассоциированного заболевания, расстройства или состояния у людей.The present invention relates to monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein and methods of using them. In various embodiments, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, antibodies of the invention are useful for activating NPR1 activity, thereby providing a means of treating or preventing an NPR1-associated disease, disorder, or condition in humans.

EA202191060A 2018-11-05 2019-10-18 ANTI-NPR1 ANTIBODIES AND THEIR APPLICATION EA202191060A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755720P 2018-11-05 2018-11-05
PCT/US2019/057033 WO2020086406A2 (en) 2018-10-23 2019-10-18 Anti-npr1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202191060A1 true EA202191060A1 (en) 2021-07-12

Family

ID=77443296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191060A EA202191060A1 (en) 2018-11-05 2019-10-18 ANTI-NPR1 ANTIBODIES AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202191060A1 (en)

Similar Documents

Publication Publication Date Title
PH12018502560A1 (en) Anti-c5 antibodies and uses thereof
PH12021550255A1 (en) Anti-npr1 antibodies and uses thereof
EA202092825A1 (en) ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION
MD3601358T2 (en) Anti-TREM2 antibodies and methods of use thereof
EA202092933A1 (en) ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS OF APPLICATION OF ANTIBODIES AND TYPES OF COMBINATION THERAPY
EA202191580A1 (en) SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
EA202190138A1 (en) ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE
CL2021000909A1 (en) Stabilizing Trem2 Antibodies
EA202092420A1 (en) ANTIBODY AGAINST PD-L1 AND ITS APPLICATION
EA202190235A1 (en) ANTIBODIES TO CD33 AND METHODS OF THEIR APPLICATION
MX2021007093A (en) Anti-btla antibodies.
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
EA201992460A1 (en) BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
MX2021004173A (en) Combinations of anti-staphylococcus aureus antibodies.
EA202092085A1 (en) THERAPEUTIC ANTIBODIES AGAINST sPLA2-GIB AND THEIR APPLICATION
MX2023007023A (en) Immunoglobulin proteins that bind to npr1 agonists.
MX2022003465A (en) Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap).
EA202191060A1 (en) ANTI-NPR1 ANTIBODIES AND THEIR APPLICATION
EA202092595A1 (en) ANTIBODIES TO SIGLEC-7 AND METHODS OF THEIR APPLICATION
EA202190056A1 (en) ANTIBODIES AGAINST FACTOR XII / XIIa AND THEIR APPLICATION
MX2018013523A (en) Dna monoclonal antibodies targeting il-6 and cd126.
EA201891800A1 (en) ANTIBODIES TO CITROLLINATED HLA-POLYPEPTIDES AND THEIR APPLICATION
MX2021003867A (en) Humanised anti-n-truncated amyloid beta monoclonal antibody.